PDGFRA and gastrointestinal stromal tumor: The one group consists of patients with GIST not harboring a drug-sensitive mutation, so-called quadruple wildtype tumor (q-wt, i.e. no KIT, PDGFRα, BRAF or SDH mutation [17–19]).